CM HOSPITALAR S/A |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.67 BRL | -13.84% |
|
-11.89% | -66.52% |
| 03-26 | CM Hospitalar S/A Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-26 | CM Hospitalar S/A Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Strengths
- Its low valuation, with P/E ratio at 3.27 and 2.91 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company shows low valuation levels, with an enterprise value at 0.35 times its sales.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -66.52% | 295M | - | ||
| +15.21% | 70.09B | C+ | ||
| -2.19% | 24.01B | C+ | ||
| +8.13% | 8.32B | B | ||
| -18.28% | 8.23B | B- | ||
| 0.00% | 8.08B | C | ||
| +19.12% | 4.41B | B+ | ||
| 0.00% | 4.12B | B- | ||
| -2.89% | 3.88B | B | ||
| +23.97% | 3.71B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- VVEO3 Stock
- Ratings CM Hospitalar S/A
